The global pyrimethamine market is expected to grow at a significant CAGR during the forecast period (2021-2027). Pyrimethamine is a protozoan infection treatment drug. It’s frequently used as an antimalarial medication (for both treatment and prevention of malaria) as well as to treat Toxoplasma gondii infections, especially when coupled with the sulfonamide antibiotic sulfadiazine in HIV-positive patients. Owing to its resistance to several plasmodium species, pyrimethamine is usually combined with sulfonamide and folinic acid. Pyrimethamine has also been shown to suppress the expression of the superoxide dismutase 1 gene, which is linked to amyotrophic lateral sclerosis.
Pyrimethamine is a folic acid antagonist that is used as an antimalarial or in combination with a sulphonamide to treat toxoplasmosis. Pyrimethamine prevents the production of purines and pyrimidines, which are required for DNA synthesis and cell proliferation, by inhibiting plasmodia dihydrofolate reductase. Nuclear division failure occurs during schizont development in erythrocytes and the liver as a result of this process. It’s often utilized as a supplement in the treatment of uncomplicated P. falciparum malaria that’s resistant to chloroquine.
To Request a Sample of our Report on Pyrimethamine Market: https://www.omrglobal.com/request-sample/pyrimethamine-market
According to the World Health Organization’s (WHO) “World Malaria Report 2018,” there were an estimated 219 million cases and over 435,000 mortalities from malaria in 2017, with Plasmodium falciparum accounting for the majority of cases. As a result, the increased prevalence of malaria is driving this market growth. Pyrimethamine is on the WHO’s list of essential medicines as one of the most critical drugs. The potential of pyrimethamine to cure protozoan and toxoplasma infections, as well as the growing number of HIV-positive patients globally and immunosuppressed individuals at risk of infections, are driving the market growth during the forecast period.
Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, was launched by Dr. Reddys Laboratories and was authorized by the US Food and Drug Administration (USFDA) in March 2020. The USFDA has authorized this generic version of Daraprim (pyrimethamine) Tablets as the sole AB-rated generic version of Daraprim (pyrimethamine) Tablets.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type – Tablets, Capsules, Injectables
- By Drug – Daraprim and Fansidar
- By End-User vertical – Hospitals and Clinics, Laboratories, and Others
Competitive Landscape: Evaluate, Pfizer Inc., Pfizer Inc. GlaxoSmithKline plc., and others.
A full Report of Pyrimethamine Market is Available @ https://www.omrglobal.com/industry-reports/pyrimethamine-market
Pyrimethamine Market Report
By Type
- Tablets
- Capsules
- Injectables
By Drug
- Daraprim
- Fansidar
- By End-User vertical
- Hospitals and Clinics
- Laboratories
- Others
Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/pyrimethamine-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
